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Orexin receptorRecent studies recognize that Hypocretin system (also known as Orexin) plays a critical role in sleep/wake
disorders and feeding behaviors. However, little is known about the regulation of theHypocretin system. It is also
known that tumor necrosis factor alpha (TNF-α) is involved in the regulation of sleep/wake cycle. Here, we test
our hypothesis that the Hypocretin system is regulated by TNF-α. Prepro-Hypocretin and Hypocretin receptor 2
(HcrtR2) can be detected at a very low level in rat B35 neuroblastoma cells. In response to TNF-α, Prepro-
HypocretinmRNA and protein levels are down-regulated, and also HcrtR2 protein level is down-regulated in B35
cells. To investigate themechanism, exogenous rat Prepro-Hypocretin and rat HcrtR2were overexpressed in B35
cells. In response to TNF-α, protein andmRNA of Prepro-Hypocretin are signiﬁcantly decreased (by 93% and 94%,
respectively), and the half-life of Prepro-Hypocretin mRNA is decreased in a time- and dose-dependent manner.
The level of HcrtR2mRNA level is not affected by TNF-α treatment; however, HcrtR2 protein level is signiﬁcantly
decreased (by 86%) through ubiquitination in B35 cells treatedwith TNF-α. Downregulation of cellular inhibitor
of apoptosis protein-1 and -2 (cIAP-1 and -2) abrogates the HcrtR2 ubiquitination induced by TNF-α. The control
green ﬂuorescent protein (GFP) expression is not affected by TNF-α treatment. These studies demonstrate that
TNF-α can impair the function of the Hypocretin system by reducing the levels of both Prepro-Hypocretin and
HcrtR2.crtR2, Hypocretin receptor 2;
cal adhesion kinase; G3PDH,
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The neuropeptides, Hypocretin-1 and Hypocretin-2 (also known as
Orexin-A and Orexin-B), were ﬁrst described in 1998 by two research
groups [1,2]. Hypocretin-1 and Hypocretin-2 are derived from a single
precursor, the Prepro-Hypocretin, through proteolytic cleavage [1,2].
Prepro-Hypocretin is expressed mainly in hypothalamic neurons, as
well as in the testis [1–3]. Two Hypocretin receptors, the Hypocretin
receptors 1 and 2 (HcrtR1 and HcrtR2), have been identiﬁed so far, and
they share 64% of homology [2,4,5]. HcrtR1 and HcrtR2 are expressed in
multiple organs, such as the brain, kidney, lung, and testis [3,4]. Prepro-
Hypocretin and Hypocretin receptors are highly conserved amongspecies [1,4,6,7]. Growing evidence supports that homeostasis of the
Hypocretin system is important for the integrity of sleep/wakefulness
cycle, feeding behavior, and emotion [8–11]. Dysregulation of the
Hypocretin system has been blamed for the sleep disorder, narcolepsy,
as well as emotion disorders, such as depression [4,9,11,12].
Tumor necrosis factor-alpha (TNF-α) is well known as a pro-
inﬂammation cytokine, and plays an important role in host defense
and pathogenesis of various diseases [13–15]. It is a 185 amino acid
glycoprotein cytokine, and was identiﬁed in 1975 [16]. TNF-α
signaling cascade is propagated by binding to TNF receptors, and,
upon activation, TNF receptors bind to TNF receptor-associated factors
and other downstream signaling proteins, resulting in regulation of
gene expression and cell functions [13–15]. TNF-α has been
associated with the development of multiple brain disorders, such
as depression, narcolepsy, multiple sclerosis, Alzheimer's disease, and
Parkinson's disease [17–20]. TNF-α is also called as adipokine due to
its role in obesity and diabetes [21]. Published data indicate that
TNF-α is involved in the regulation of sleep/wakefulness cycle and
fatigue during infections [22]; but, the mechanism is not completely
understood.
In the present study, we demonstrate that TNF-α can impair the
Hypocretin system through a decrease of mRNA half-life and protein
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Hypocretin mRNA, resulting in downregulation of both protein and
mRNA levels of Prepro-Hypocretin. TNF-α treatment decreases
HcrtR2 protein level through a ubiquitination pathway mediated by
cellular inhibitor of apoptosis protein-1 and -2 (cIAP-1 and cIAP-2),
without affecting the mRNA level of HcrtR2. These data for the ﬁrst
time provide evidence that TNF-α can directly downregulate the
Hypocretin system, suggesting a role of TNF-α in the development of
disorders caused by the impaired Hypocretin system.
2. Materials and methods
2.1. Reagents
Recombinant tumor necrosis factor alpha (TNF-α) was obtained
from R&D Systems (Minneapolis, MN). The following puriﬁed poly-
clonal antibodies were purchased: anti-Prepro-Hypocretin (Milliopore,
Billerica, MA), anti-HcrtR2, anti-focal adhesion kinase (FAK), and anti-
Green Fluorescent Protein (GFP) (Santa Cruz Biotechnology, Santa Cruz,
CA). The following puriﬁed monoclonal antibodies (mAb) were
purchased: anti-glyceraldehyde 3-phosphate dehydrogenase (G3PDH)
(Research Diagnostics, Flanders, NJ) and anti-human/mouse pan
cellular inhibitor of apoptosis protein-1 and -2 (cIAP1 and cIAP2)-
speciﬁc antibody whichwas obtained from R&D Systems (Minneapolis,
MN). All other reagents were purchased from Thermo Fisher Scientiﬁc
(P-SUWANEE, GA), Sigma-Aldrich (St. Louis,MO), or Bio-Rad (Hercules,
CA).
2.2. Cell culture and MSCV retroviral vectors
The B35 rat neuroblastoma cells were derived from the central
nervous system, and obtained from American Type Culture Collection
(ATCC, Manassas, VA). Cells were maintained and propagated in
Dulbecco's modiﬁed Eagle's medium(DMEM) supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, and 100 U/ml penicillin/
streptomycin/gentamycin as described [23]. Stable cell lines expressing
Prepro-Hypocretin and HcrtR2 were established using the MSCV
Retroviral Expression Vector System (with the Neomycin resistance
gene) purchased from Clontech (Mountain View, CA) and used
according to the manufacturer's instructions. Brieﬂy, rat Prepro-
Hypocretin cDNA (gene accession #AF041241) or rat HcrtR2 cDNA
(gene accession #AF041246) was ﬁrst inserted into the MSCV vectors
between the EcoRI site and the XhoI site of the polylinker locatedwithin
the multiple cloning sites of the MSCV vector. Then, the MSCV-Prepro-
Hypocretin vector or MSCV-HcrtR2 vector was transfected into the
packaging cells (Clontech) by liposome-mediated transfections
(Lipofectamine 2000, from Invitrogen, Carlsbad, California) to produce
infectious, but replication-incompetent, retroviral particles, and the
collected supernatants containing retroviral particles were used to
transfect the B35 cells. Stable clones were selected by Neomycin as the
MSCV vector contains the Neomycin resistance gene. The green-
ﬂuorescent-protein (GFP) proteinwas also subcloned intoMSCVvector,
and MSCV-GFP was used as a control and also used to optimize the
transfection and selection conditions. GFP-positive cells were easily
detected under a ﬂuorescent microscope (Nikon, Japan, Model: Eclipse,
Ti).
2.3. Western blotting and immunoprecipitation
This was essentially as previously described by us [23]. Brieﬂy, cells
were lysed in 1% NP-40 lysis buffer containing the following inhibitors,
100 μM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 100 μM sodium
vanadate, and 20 μg/ml TLCK. Protein concentration of whole cell or
whole lung lysate was determined by BCA kit (Pierce, Rockford, IL).
Equivalent micrograms of whole cell lysates was electrophoresed on
SDS PAGE, transferred to Immobilon-P membrane (Millipore Corp.,Bedford,MA), probed or stripped followed by re-probingwith indicated
antibodies, and developed with ECL system (Pharmacia Biotech,
Piscataway, NJ). UbiquitinatedHcrtR2 levelwasdetermined byWestern
blotting under non-disulﬁde-reduced conditions following immuno-
precipitation of equivalent cell lysates as described previously [24]. The
expressionof G3PDHproteinwasused as a loading control. Quantitative
analysis (densitometry) ofWestern blots was performed by calculating
the relative density (pixel density) of the immunoreactive bands after
acquisition of the blot image (scanning) and analysis with Adobe
Photoshop software as described [23]. The background of densitometric
reading on the ECL-developed ﬁlm was subtracted.
2.4. siRNA studies
Transfection of siRNA was done as described previously [24].
Commercially available small interfering RNA (siRNA) duplexes
directed against rat cIAP1 and cIAP2 were purchased from Invitrogen
(Carlsbad, California) as described [25], and are all selected and
validated Stealth siRNAs. Control siRNA duplexes were purchased
from Dharmacon (Lafayette, CO). Lamin A/C siRNA (Dharmacon) was
used to optimize the transfection conditions and efﬁciency. Additional
controls of nonspeciﬁc siRNA duplex or vehicle alone were evaluated
and found not to alter cIAP-1 and cIAP-2 mRNA and protein
expression at the concentration of siRNA found to reduce the speciﬁc
target message and protein optimally.
2.5. RT-PCR and real-time quantitative RT-PCR
Total RNAwas extracted fromcells using theRNeasyMiniKit (Qiagen,
Inc., Valencia, CA), and 1 μg of total RNAwas reverse transcribed to cDNA
for RT-PCR and real-time quantitative RT-PCR as described previously
[26]. Quantitative RT-PCR analysiswas carried outwith the SYBR®Green
PCR Master Mix (Applied Biosystems, Foster City, CA) using the Biorad
iQ5 Real-Time PCR Detection System, according to the manufacturer's
instructions. The quantitative RT-PCR was performed using 4 l of the
synthesized cDNA, 12.5 μl of SYBR®GreenPCRMasterMix, 1 μl of primer,
and 7.5 μl of water in a ﬁnal 25 μl volume. Samples were assayed in
triplicate, and the values were normalized to the relative amounts of
beta-actin mRNA level. Primer sequences were as described [3]. Primers
for Prepro-Hypocretin: sense 5′-GCCGTCTCTACGAACTGTTG-3′ and anti-
sense 5′-GAGGAGAGGGGAAAGTTAG-3′; for HcrtR2: sense 5′-
CAATGTTGTTGGGGTGCTTA-3′ and antisense 5′-TCCCCCTCTCA-
TAAACTTGG-3′; for rat focal adhesion kinase (FAK) (gene accession
#NM_013081): sense 5′-CCTTAACAATGCGCCAGTTT-3′ and antisense
5′-CCAGATACGCGAGTGCTGTA-3′; and for Beta-actin: sense 5′-
GTGGGTATGGGTCAGAAGGA-3′ and antisense 5′-AGCGCGTAACCCTCA-
TAGAT-3′. All primers were purchased from Fisher Scientiﬁc.
2.6. mRNA stability assay
mRNA half-life was determined by culturing B35 cells in a medium
with actinomycin D (10 μg/ml) to block transcription as described by
Lindholm et al. [27]. Brieﬂy, immediately after addition of actinomycin
D, B35 cells were treated with TNF-α or vehicle for the indicated time,
and harvested. Total RNA was collected, and the amounts of Prepro-
Hypocretin or HcrtR2 mRNA at each time point were quantiﬁed by
real-time RT-PCR, and normalized to the amounts of β-actin mRNA at
the same time point as described [26].
2.7. Statistical analysis
Data were analyzed using the unpaired or paired t-test analysis
(for comparisons between two groups) (Sigma Plot, SPSS Inc.), and
expressed as means±SE. Experiments were performed two to four
times with duplicates. Linear regression was performed by using
Fig. 1. TNF-α treatment signiﬁcantly decreases endogenous Prepro-Hypocretin mRNA
and protein levels, as well as endogenous HcrtR2 protein level in rat B35 cells. Rat B35
neuroblastoma cells were cultured in the presence and absence of TNF-α cytokine
(2 ng/ml) for 24 h at 37 °C. Panel A: Low levels of endogenous Prepro-Hypocretin and
HcrtR2 were detected by RT-PCR as described in Materials and methods in B35 cells
without TNF-α treatment. Reactions without reverse transcriptase (RTase) were PCR
controls. Panels B, D, and F: Total RNA in B35 cells treated with or without TNF-α was
extracted to analyze the Prepro-Hypocretin mRNA level in panel B, the HcrtR2 mRNA
level in panel D, and the control FAK mRNA level in panel F, by quantitative real time
RT-PCR (normalized to beta-actin and relative to the controls: the cells treated with
vehicle only). Panels C and E: The aforementioned B35 cells were lysed, and equivalent
amount of whole cell detergent lysates wasWestern blotted to analyze the protein level
of Prepro-Hypocretin and HcrtR2 with the indicated antibodies. FAK and G3PDH
expression served as controls.
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signiﬁcant.
3. Results
3.1. Prepro-Hypocretin mRNA and protein levels, and Hypocretin
receptor 2 (HcrtR2) protein levels, are signiﬁcantly down-regulated in
response to tumor necrosis factor-alpha (TNF-α) treatment
Expression of Prepro-Hypocretin (the common precursor of
Hypocretin-1 and -2) was detected at a very low level in the B35 rat
neuroblastoma cell line by RT-PCR and Western blot analysis (Fig. 1A
and C, respectively). In response to TNF-α treatment (2 ng/ml, for
24 h at 37 °C), both mRNA and protein of Prepro-Hypocretin were
signiﬁcantly down-regulated (Fig. 1B and C).
HcrtR2 expressionwas alsodetected at a very low level in theB35 rat
neuroblastoma cell line by RT-PCR and Western Blot analysis (Fig. 1A
and E, respectively). In response to TNF-α treatment (2 ng/ml, for 24 h
at 37 °C), the protein level of HcrtR2 was signiﬁcantly down-regulated
(Fig. 1E). TNF-α had no detectable effect on the HcrtR2 mRNA level
(Fig. 1D). Focal adhesion kinase (FAK) is a cytoplasmic protein kinase,
and FAK is well known for its key role in cell migration [28,29]. Both
mRNA and protein levels of FAK were not altered in TNF-α-treated B35
cells (Fig. 1C, E, and F), and the expression of FAK was used as a control.
3.2. Exogenous Prepro-Hypocretin and HcrtR2 expression mediated by
retroviral vectors in B35 cells
As the endogenous expression of Prepro-Hypocretin and HcrtR2
are very low in the B35 rat neuroblastoma cell line (Fig. 1), exogenous
rat Prepro-Hypocretin and rat HcrtR2 were overexpressed in these
cells to facilitate our study to understand the mechanism. The MSCV
retroviral expression system was used to generate the stable cell lines
overexpressing rat Prepro-Hypocretin and HcrtR2 in B35 cells as
described inMaterials andmethods. HcrtR2was selected since animal
studies demonstrate that HcrtR2 is themajor receptor for the function
of Hypocretins [30].
The MSCV vector containing the green-ﬂuorescent-protein (GFP)
cDNA (MSCV-GFP) and empty MSCV vector were used as controls, and
MSCV-GFP was used to establish the GFP-expressing control B35 cells.
Greater than 95% of B35 cells were GFP-positive after MSCV-GFP
infection and selected by neomycin resistance (Fig. 2A). Prepro-
Hypocretin overexpression mediated by MSCV-Prepro-Hypocretin
vector was conﬁrmed byWestern blot (Fig. 2B). HcrtR2 overexpression
mediated by MSCV-HcrtR2 vector was also conﬁrmed by Western blot
(Fig. 2C). GFP expression mediated by the MSCV-GFP vector had no
effect on expression of Prepro-Hypocretin, HcrtR2, or FAK (Fig. 2B andC,
respectively).
3.3. TNF-α signiﬁcantly decreases the mRNA and protein levels of
Prepro-Hypocretin
To examine the effect of TNF-α treatment on Prepro-Hypocretin
expression in B35 cells transfected with MSCV-Prepro-Hypocretin
vector, cells were cultured in the presence and absence of TNF-α
cytokine (2 ng/ml) for 24 h at 37 °C. Cells were then subsequently
lysed and analyzed by Western blotting for the protein level of
Prepro-Hypocretin in response to TNF-α treatment. Total RNA was
also extracted from these cells to analyze the mRNA level of Prepro-
Hypocretin by quantitative real time RT-PCR. Prepro-Hypocretin
protein level in cells treated with TNF-α was signiﬁcantly decreased
(by 93%, pb0.01) when compared to that in cells treated with vehicle
only (Fig. 3A and B). Prepro-Hypocretin mRNA level in cells treated
with TNF-α was also signiﬁcantly decreased (by 94%, pb0.01) when
compared to that in cells treated with vehicle only (Fig. 3C). TNF-α
treatment had no effect on the control GFP expression (Fig. 3E), andhad no effect on the FAK mRAN and protein level (Fig. 3D and E). The
data indicate that TNF-α induces a signiﬁcant reduction of bothmRNA
and protein expression of Prepro-Hypocretin, evidenced by results
obtained from both endogenous and exogenous Prepro-Hypocretin
(Figs. 1 and 3, respectively).
3.4. Stability of Prepro-Hypocretin mRNA is decreased in a time-dependent
and dose-dependent manner in response to TNF-α treatment
To understand the mechanism resulting in the reduction of both
mRNA and protein levels of Prepro-Hypocretin in response to TNF-α, we
examined the decay/degradation of Prepro-Hypocretin mRNA in B35
cells overexpressing the Prepro-Hypocretin (mediated byMSCV-Prepro-
Fig. 2. Prepro-Hypocretin and HcrtR2 overexpression mediated by MSCV vectors in rat B35 cells.MSCV retroviral vectors were used to generate stable cell lines overexpressing the
Prepro-Hypocretin, HcrtR2, or control GFP protein in rat B35 neuroblastoma cells as described in Materials and methods. Panel A: Fluorescence microscopic analysis found that over
95% of B35 cells infected withMSCV-GFP vector were GFP positive (per high power ﬁeld, n=10 per clone), indicating a high efﬁciency of infection. The cell clone infectedwith empty
MSCV vector served as a control for MSCV-GFP vector. Panels B and C: MSCV-Prepro-Hypocretin and MSCV-HcrtR2 vectors were used to express Prepro-Hypocretin and HcrtR2 in
B35 cells, respectively. Cells were lysed, and equivalent amount of whole cell detergent lysates wasWestern blotted with the indicated antibodies. FAK and G3PDH protein served as
controls.
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signiﬁcant reduction of the half-life of Prepro-Hypocretin mRNA when
compared to that in vehicle-treated cells (Fig. 4A). The half life of Prepro-
Hypocretin was about 50 min in TNF-α-treated cells; in contrast, it is
more than 160 min in controls (Fig. 4A). The data also demonstrate that
thedecay/degradation of Prepro-HypocretinmRNA in response to TNF-α
was both time-dependent (Fig. 4A) and dose-dependent (Fig. 4B).
3.5. TNF-α signiﬁcantly decreases the protein level of HcrtR2 without
affecting the level of HcrtR2 mRNA
To examine the effect of TNF-α treatment on Hypocretin receptor
expression, B35 cells overexpressing the HcrtR2 (mediated by MSCV-
HcrtR2 vector as shown in Fig. 2) were cultured in the absence and
presence of TNF-α (2 ng/ml) for 24 h at 37 °C. Protein and mRNA
levels of HcrtR2 in TNF-α-treated cells were determined by Western
blot analysis and quantitative real-time RT-PCR, respectively. As
shown in Fig. 5, TNF-α treatment resulted in a signiﬁcant reduction of
HcrtR2 protein level. In response to TNF-α, HcrtR2 protein level was
decreased by 86% (pb0.01) when compared to that in vehicle-treated
cells (Fig. 5A and B). In contrast, the mRNA level of HcrtR2 was similar
between TNF-α-treated cells and vehicle-treated cells (Fig. 5C).
3.6. TNF-α induces ubiquitination of HcrtR2 through a pathway mediated
by cellular inhibitor of apoptosis proteins
To determine themechanism contributing to the reduction of HcrtR2
protein level in response to TNF-α treatment, the involvement of
ubiquitination was studied in B35 cells overexpressing the HcrtR2. The
association of ubiquitinwithHcrtR2 in TNF-α-treated cells (2 ng/ml, 6 h)
was conﬁrmed byWestern blot analysis following immunoprecipitation
(IP) of HcrtR2 (Fig. 6A). Cellular inhibitor of apoptosis protein-1 and -2
(cIAP1 and cIAP2) functions as E3 ubiquitin-protein ligases within the
TNF-α signaling pathway, and the E3 ubiquitin-protein ligase is required
for theﬁnal step of the ubiquitylation cascade [25]. To determine the role
of cIAPs in TNF-α-induced ubiquitination of HcrtR2, small interfering
RNA (siRNA) speciﬁcally targeting cIAP1 or cIAP2 was utilized to
knockdown the cIAP expression in B35 cells overexpressing the HcrtR2.
The expression of cIAP1 and cIAP2was signiﬁcantly decreased by siRNAs
at both protein level (Fig. 6B) and mRNA level (data not shown).
Downregulationof either cIAP1 or cIAP2expressionpartially restored the
HcrtR2 protein level in TNF-α-treated cells (Fig. 6B). Downregulation of
both cIAP1 and cIAP2 expression was required to abrogate the TNF-α-
induced ubiquitination of HcrtR2, and to restore the HcrtR2 expression(Fig. 6B). Non-speciﬁc siRNA controls had no effect on HcrtR2 or cIAP
expression as shown in Fig. 6B.
4. Discussion
4.1. The Hypocretin system is impaired by TNF-α treatment
In the present study, we describe and characterize a new function
of TNF-α as an inhibitory regulator of the Hypocretin system. The
effect of TNF-α treatment on Hypocretin system was studied by
examining the expression (mRNA and protein levels) of two key
components of the Hypocretin system, the Prepro-Hypocretin and
HcrtR2. Prepro-Hypocretin is the common precursor of both Hypo-
cretin-1 and Hypocretin-2. HcrtR2 was selected because HcrtR2 is the
major Hypocretin receptor according to the ﬁndings in animal studies
[30].
Our data show that TNF-α treatment decreases the mRNA and
protein levels of Prepro-Hypocretin through enhancing the decay of
Prepro-Hypocretin mRNA. TNF-α treatment also decreases the
expression of HcrtR2 through the ubiquitination pathway. cIAP-1
and cIAP-2 are two key mediators of the HcrtR2 ubiquitination
pathway induced by TNF-α, and downregulation of both cIAP-1 and
cIAP-2 is required to abrogate the TNF-α-induced ubiquitination of
HcrtR2. These data for the ﬁrst time provide evidence that TNF-α
functions as a negative regulator of the Hypocretin system, suggesting
a potentialmechanismbywhich TNF-α is involved in the pathogenesis
of disorders caused by an impaired Hypocretin system.
4.2. TNF-α downregulates Prepro-Hypocretin through increasing
Prepro-Hypocretin mRNA degradation
In response to TNF-α treatment, both Prepro-Hypocretin protein and
mRNA levels are signiﬁcantly decreased (by 93% and 94%, respectively)
when compared to that in cells treated with vehicle only. The TNF-α-
induced Prepro-Hypocretin reduction is likely the result of the increased
decay/degradation of mRNA, since the half-life of Prepro-Hypocretin
mRNA is decreased in TNF-α-treated cells. It has been previously
demonstrated that TNF-α can negatively regulate gene expression.
TNF-α treatment (10 ng/ml) decreases the expression of both endothe-
lial nitric oxide synthase and argininosuccinate synthase in aortic
endothelial cells [31]. It is also known that TNF-α regulates mRNA
stability through modulation of the expression of the AU-rich element
(ARE) binding proteins [32]. AREbinding proteins, such as tristetraprolin,
target the mRNAs containing an ARE in the 3′ untranslated region, and
Fig. 3. TNF-α treatment signiﬁcantly decreases Prepro-Hypocretin expression in B35 cells
transfected with MSCV-Prepro-Hypocretin vector. B35 cells overexpressing Prepro-
Hypocretin (mediated byMSCV-Prepro-Hypocretin vector) or overexpressing GFP control
protein (mediated by MSCV-GFP) were cultured in the presence and absence of TNF-α
cytokine (2 ng/ml) for 24 h at 37 °C. Panels A and E: Cells were lysed, and equivalent
amount ofwhole cell detergent lysateswasWesternblottedwith the indicated antibodies.
FAK and G3PDH protein expression served as controls. Panel B: Densitometry of Prepro-
Hypocretin expression as shown in panel A (normalized to G3PDH and relative to the
controls: the cells treated with vehicle only) as described in Section 2.3. Panels C and D:
Total RNA was extracted from the aforementioned cells to analyze the mRNA level of
Prepro-Hypocretin (in panel C) and FAK (in panel D as a control) by quantitative real time
RT-PCR. Data was normalized to beta-actin and relative to the control (cells treated with
vehicle only). For panels B and C, open bar denotes the results from control cells (vehicle
only), and black bar denotes the results from TNF-α-treated cells. Data are presented as
mean±S.D. (n=4). *Represents pb0.01 for TNF-α-treated cells compared to vehicle-
treated control group.
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Fig. 4. TNF-α treatment increases Prepro-Hypocretin mRNA decay. Panel A: B35 cells
overexpressing the Prepro-Hypocretin were cultured in the presence and absence of
TNF-α cytokine (2 ng/ml) for indicated time points at 37 °C. Total RNA was collected, and
the amount of Prepro-Hypocretin mRNA at each time point was quantiﬁed by real-time
RT-PCR as in Fig. 2. Panel B: B35 cells overexpressing the Prepro-Hypocretinwere cultured
in the absence or presence of TNF-α cytokine at the indicated concentrations for 40 min at
37 °C, and analyzed as in panel A. Solid line in panel A or open bar in panel B denotes the
results from control cells (vehicle only). Dotted line or black bar denotes the results from
TNF-α-treated cells. Data are presented as mean±S.D. (n=3 to 4). *Represents pb0.01
for TNF-α-treated cells compared to vehicle-treated control group.
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that TNF-α regulates the stability of Prepro-Hypocretin mRNA through
ARE-binding proteins, and the exact mechanism will be the focus of
future study.
4.3. TNF-α downregulates HcrtR2 through cIAP-mediated ubiquitination
Our data also demonstrate that TNF-α decreases HcrtR2 through
the ubiquitination pathway, and this pathway is mediated by cIAP-1
and cIAP-2. This is evidenced by that downregulation of either cIAP-1or cIAP-2 can only partially block the inhibitory effect of TNF-α on
HcrtR2 expression. Downregulation of both cIAP-1 and cIAP-2 is
required to abrogate the inhibitory effect of TNF-α on HcrtR2
expression, and to restore the HcrtR2 level. cIAP-1 and cIAP-2 are
binding partners of the TNF-associated factors 1 and 2 {877}. cIAPs are
important regulators of cell survival and death signaling, as cIAPs
directly bind caspases and inhibit caspase-mediated cell death
signaling [33]. Recent data demonstrate that cIAP-1 and cIAP-2 also
function as E3 ligases, and the association of E3 ligase with target
proteins is a critical step of the E ligase cascade before protein
ubiquitination [25]. It has been demonstrated that cIAP-1 and cIAP-2
are required for the ubiquitination of the receptor interacting protein
(RIP) involved in TNF signaling [25]. Based on these data, we speculate
that cIAP-1 and cIAP-2 function as E3 ligases and mediate the HcrtR2
ubiquitination induced by TNF-α, and this remains to be elucidated in
future.4.4. TNF-α, Hypocretin system, and sleep disorders
TNF-α is well known for its role in inﬂammation, host defense, and
pathogenesis of various diseases. Published data indicate that TNF-α is
involved in regulation of sleep–wakefulness behavior and fatigueduring
infections and depression [14,17,20,22]. Elevated plasma TNF-α level
Fig. 5. TNF-α treatment decreases HcrtR2 expression in B35 cells transfected with MSCV-HcrtR2 vector. B35 cells overexpressing the HcrtR2 (mediated by MSCV-HcrtR2) were
cultured in the presence and absence of TNF-α cytokine (2 ng/ml) for 24 h at 37 °C. Panel A: Cells were lysed, and equivalent amount of whole cell detergent lysates was Western
blotted with the indicated antibodies. Panel B: Densitometry of HcrtR2 expression as in Fig. 2. Panel C: mRNA level of HcrtR2 was analyzed by quantitative real time RT-PCR as in
Fig. 2. Data are presented as mean±S.D. (n=4). *Represents pb0.01 for TNF-α-treated cells compared to vehicle-treated control group.
570 S. Zhan et al. / Biochimica et Biophysica Acta 1812 (2011) 565–571has been reported in patientswith excessive daytime sleepiness, such as
obstructive sleep apnea and idiopathic hypersomnia [18–20,34].
Elevated TNF-α level is also detected in patients with narcolepsy;
but, this ﬁnding is not supported by others [14,17–19]. Narcolepsy
patients have excessive daytime sleepiness [35,36]. Animal studies
convincingly support a role of TNF-α signaling in regulation of sleep
and wakefulness. Data obtained from rabbits or rodents demonstrate
that loss of TNF-α signaling decreases or suppresses sleep [37–39],
while exogenous TNF-α administration increases sleep [40,41].
Published data also demonstrate that serum TNF-α level increasesFig. 6. TNF-α treatment induces HcrtR2 ubiquitination through a pathway mediated by
cIAP-1 and cIAP-2. Panel A: B35 cells overexpressing the HcrtR2 were cultured in the
presence and absence of TNF-α cytokine (2 ng/ml) for 6 h at 37 °C. Cells were lysed, and
equivalent amount of whole cell detergent lysates was immunoprecipitated (IP) by
anti-HcrtR2 IgG, followed byWestern blot analysis with the indicated antibodies. Panel
B: B35 cells constitutively expressing the HcrtR2 were transfected with siRNA directed
toward cIAP-1 or/and cIAP-2 as described in Section 2.4, and then cultured in the
presence and absence of TNF-α cytokine (2 ng/ml) for 24 h at 37 °C. Cells were
harvested, and equivalent amount of whole cell detergent lysates was Western blotted
with the indicated antibodies. Experiment was repeated three times, and representa-
tive images are shown.by an average of 8% for each hour reduction in sleep [42], further
supporting an association between TNF-α signaling and the sleep–
wake cycle regulation.
Our data suggest that TNF-α can be involved in the development of
sleep and other related disorders by impairing the function of the
Hypocretin system. The Hypocretin system can be impaired in
situations with transiently or persistently increased TNF-α level.
The Hypocretin system is considered as a critical regulator of sleep/
wakefulness cycle, feeding behavior, emotion, and rewarding system
[8–10]. Prepro-Hypocretin knockout mice develop a phenotype
similar to narcolepsy, such as fragmented sleep–wake cycles [8].
Hypocretin-1 level in cerebrospinal ﬂuid is decreased in a narcolepsy
patient with cataplexy [43,44]. Higher body mass index is associated
with sleep disorders (such as narcolepsy and severe obstructive sleep
apnea), as well as increased plasma TNF-α level [45–49]. The potential
role of Hypocretin in treating breathing disorders associated with
sleep has also been proposed [50,51]. So far, very little is known about
the mechanism(s) by which Hypocretin system is regulated during
these disorders. Our data show that the Hypocretin system can be
impaired by TNF-α. Whether this ﬁnding could be related to the
excessive daytime sleepiness in patients remains to be elucidated.
Our limitation is that themajority of the workwas performed in an
overexpressed system. Similar results were also obtained by using the
endogenous system; however, due to technical reasons, the mecha-
nisms were further elucidated with the overexpressed system. Other
publications also use this strategy (overexpression) to delineate the
physiological effects of Hypocretin/Orexin receptors in human
embryonic kidney (HEK) 293 cells or in Chinese hamster ovary
(CHO) cells [52–54]. Using primary cells that express signiﬁcant
amount of Hypocretin/Orexin or receptors has been considered;
however, this is a big challenge as the number of cells in the brain
expressing Hypocretin/Orexin is very limited [1,2], and these primary
cells are difﬁcult to maintain in vitro.4.5. Conclusions
In conclusion, our work for the ﬁrst time provides evidence that the
Hypocretin system can be impaired by TNF-α directly. TNF-α treatment
decreases the expression of both Prepro-Hypocretin and HcrtR2 either
through enhancing the decay of Prepro-Hypocretin mRNA or through
HcrtR2 ubiquitination mediated by cIAP-1 and cIAP-2. Our ﬁndings
suggest a potential mechanism by which TNF-α is involved in the
pathogenesis of disorders caused by an impaired Hypocretin system,
and add a new dimension to the biological activities of TNF-α that may
have important implications in health care and diseases.
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